Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Dyne Therapeutics, Inc. DYN
$13.28
-$0.31 (-2.35%)
На 18:00, 12 мая 2023
+54.37%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
781585228.00000000
-
week52high
15.63
-
week52low
4.30
-
Revenue
0
-
P/E TTM
-4
-
Beta
0.24047900
-
EPS
-3.60000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 12:30
Описание компании
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | 20 июл 2022 г. | |
| Raymond James | Outperform | 12 июл 2022 г. | |
| Piper Sandler | Overweight | Overweight | 23 мая 2022 г. |
| Raymond James | Outperform | Outperform | 04 ноя 2022 г. |
| Piper Sandler | Overweight | 12 окт 2020 г. | |
| JP Morgan | Overweight | Overweight | 29 ноя 2022 г. |
| Guggenheim | Buy | 26 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| McNeill Jonathan | D | 68528 | 10000 | 18 янв 2023 г. |
| McNeill Jonathan | D | 67600 | 10000 | 18 янв 2023 г. |
| McNeill Jonathan | A | 77600 | 10000 | 18 янв 2023 г. |
| McNeill Jonathan | D | 67600 | 30150 | 09 янв 2023 г. |
| Atlas Venture Opportunity Fund II, L.P. | A | 934581 | 934581 | 12 дек 2022 г. |
| Rhodes Jason P | A | 934581 | 934581 | 12 дек 2022 г. |
| Scalzo Richard William | D | 56183 | 312 | 12 дек 2022 г. |
| Beskrovnaya Oxana | D | 90145 | 680 | 12 дек 2022 г. |
| Brumm Joshua T | D | 329801 | 3322 | 12 дек 2022 г. |
| Farwell Wildon | D | 100096 | 628 | 12 дек 2022 г. |
Новостная лента
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
GlobeNewsWire
03 мая 2023 г. в 07:35
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the BofA Securities 2023 Healthcare Conference in Las Vegas on Wednesday, May 10, 2023 at 11:35 a.m. PT (2:35 p.m. ET).
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
GlobeNewsWire
02 мая 2023 г. в 16:46
- FORCE Delivers to CNS in Non-Human Primates - - FORCE Achieves Robust Reduction of Toxic Nuclear DMPK RNA and Foci in Brain of a DM1 Disease Model -
Dyne Therapeutics to Present at Upcoming Investor Conferences
GlobeNewsWire
07 мар 2023 г. в 07:30
WALTHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in virtual fireside chats at the following investor conferences:
Diving Into Dyne Therapeutics
Seeking Alpha
19 янв 2023 г. в 17:01
Shares of genetic muscle disease concern Dyne Therapeutics, Inc. have enjoyed a recent bounce on the back of good news from a rival, more than tripling in price. The recent news somewhat validated/de-risked its oligonucleotide approach to treating muscle diseases, as its first two programs entered the clinic in September 2022.
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
Zacks Investment Research
18 янв 2023 г. в 10:33
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.